Reports Q3 revenue $51.298M, consensus $50.71M. “Rhythm delivered continued momentum during the third quarter, highlighted by the FDA acceptance of our supplemental new drug application for acquired hypothalamic obesity and steady growth from our Bardet-Biedl syndrome commercial efforts.” said David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm. “With the FDA’s PDUFA goal date on HO on December 20, a strong cash position and continued progress across our melanocortin-4 receptor pathway pipeline, the Company is well positioned to deliver sustained, long-term growth.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Is RYTM a Buy, Before Earnings?
- Rhythm Pharmaceuticals’ Setmelanotide Trial: A Potential Game-Changer in Obesity Treatment
- Rhythm Pharmaceuticals Advances Setmelanotide Study for Prader-Willi Syndrome
- Rhythm Pharmaceuticals’ RM-718 Study: A Potential Game-Changer in Obesity Treatment
- Rhythm Pharmaceuticals’ Setmelanotide Study: A Promising Step in Rare Obesity Treatment